WO/2016/009401 PREPARATION OF TEDIZOLID PHOSPHATE||WO||21.01.2016|
||PCT/IB2015/055428||DR. REDDY'S LABORATORIES LIMITED ||SUD, Abhishek |
The present application relates to processes for the preparation of tedizolid phosphate.
WO/2016/005960 PROCESS FOR PREPARATION OF LIRAGLUTIDE||WO||14.01.2016|
||PCT/IB2015/055273||DR. REDDY'S LABORATORIES LIMITED ||GANDAVADI, Sunil Kumar |
The present application relates to improved processes for the preparation of Liraglutide.
WO/2016/001851 PREPARATION OF TICAGRELOR||WO||07.01.2016|
||PCT/IB2015/054947||DR. REDDY'S LABORATORIES LIMITED ||DAHANUKAR, Vilas |
The present application relate to processes for preparing Ticagrelor and to intermediates that are useful in the processes.
WO/2015/200341 SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN||WO||30.12.2015|
||PCT/US2015/037214||DR. REDDY'S LABORATORIES LTD. ||SASMAL, Pradip, Kumar |
The present application relates to a series of substituted imidazo[l,2-a]pyridine compounds of formula (I), pharmaceutically acceptable salts, pharmaceutically acceptable solvates or stereoisomers thereof, their use as tropomyosin receptor kinase (Trk) family protein kinase inhibitors, method of making and pharmaceutical compositions comprising such compounds.
WO/2015/193786 METHOD OF PURIFYING ANTI-IDIOTYPIC ANTIBODIES||WO||23.12.2015|
||PCT/IB2015/054502||DR. REDDY'S LABORATORIES LIMITED ||MEDISETTY, Rajesh |
The present invention discloses a method for purifying anti-idiotypic antibodies using a series of purification via chromatographic columns, wherein the columns comprise targeted antibody coupled affigel hydrazide column; human IgG coupled affigel hydrazide column; and human IgG coupled NHS activated sepharose. Further, the anti-idiotypic antibodies obtained from the said method contains higher specificity and negligible cross reactivity.
WO/2015/151056 MAB-FCRN ASSAY||WO||08.10.2015|
||PCT/IB2015/052429||DR. REDDY'S LABORATORIES ||SUBRAMANYAM, Satyam|
The present invention relates to methods and means for determining the relative binding activity of a therapeutic antibody based on the affinity of said antibody for a specific binding partner thereof. In particular, this invention relates to methods and means for use in FcRn binding assays wherein the competitive binding assay is performed between labelled Mab with F(ab')2 immune complex and unlabeled therapeutic X-Mab with the F(ab')2 immune complex to bind to the FcRn receptors. The assay as disclosed in tthe present invention picks up changes in Fc region like oxidation that impact FcRn binding. The assay is not influenced by minor differences in percent aggregates between therapeutic samples and hence be used for comparability assessment of one or more samples for binding to FcRn.
WO/2015/140700 CELL CULTURE PROCESS||WO||24.09.2015|
||PCT/IB2015/051930||DR. REDDY'S LABORATORIES LIMITED ||THUDUPPATHY, Guru|
The invention discloses a cell culture process comprising culturing cells in the presence of betaine to obtain a glycoprotein with a glycoform composition comprising increased percentage of afucosylated glycans. Further, the invention 5 discloses a cell culture process comprising manganese, galactose and betaine for obtaining a glycoprotein with a glycoform composition comprising target values of mannosylated, galactosylated and afucosylated glycans.
WO/2015/132745 METHOD FOR DETECTION OF NEUTRALIZING ANTI-RITUXIMAB ANTIBODIES||WO||11.09.2015|
||PCT/IB2015/051602||DR. REDDY'S LABORATORIES LIMITED ||VEMURI, Sireesha|
This invention is related to a method of detecting neutralizing activity of anti rituximab antibodies in a rheumatoid factor positive rheumatoid arthritis patient's sample, wherein the method retrieves anti-rituximab antibodies using an acidic buffer compatible with cell based CDC assay. In addition, the method employs use of 5 magnetic beads coupled rituximab for the retrieval of ARiA. The said method is able to measure the neutralizing anti-rituximab antibodies in presence of higher amounts of free rituximab and RF.
WO/2015/128795 PROCESS FOR MODIFYING GALACTOSYLATION AND G0F CONTENT OF A GLYCOPROTEIN COMPOSITION BY GLUTAMINE SUPPLEMENTATION||WO||03.09.2015|
||PCT/IB2015/051367||DR. REDDY'S LABORATORIES LIMITED ||KADREPPA, Sreenath|
The invention relates to a cell culture process for decreasing the galactosylated content and/or increasing the G0F content of a glycoprotein. The process involves subjecting recombinant cells expressing the said glycoprotein to a temperature and pH shift and supplementing cell culture with glutamine.
WO/2015/125113 METHOD OF CULTURING HIGH CELL DENSITY PBMC'S||WO||27.08.2015|
||PCT/IB2015/051293||DR. REDDY'S LABORATORIES LIMITED ||MEHTA, Gaurav Rajendraprasad|
The present invention relates to a method of attaining high cell density PBMCs that are viable for longer duration in culture. In particular the method involves culturing the cells in lymphocyte growth medium comprising recombinant human interleukin-2 and human serum to acquire cells with a density as high as 108 cells/ml. PBMCs thus obtained remains functionally viable for 25 to 30 days in culture and are also found enriched in NK cell content allowing it to be widely used as effector cells, particularly T-cell response assays.